Increased CD38 expression in T cells and circulating anti-CD38 IgG autoantibodies differentially correlate with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients.

CD38 is a multifunctional protein possessing ADP-ribosyl cyclase activity responsible for both the synthesis and the degradation of several Ca(2+)-mobilizing second messengers. In mammals, CD38 also functions as a receptor. In this study CD38 expression in CD4(+), CD8(+), or CD25(+) T cells was significantly higher in systemic lupus erythematosus (SLE) patients than in Normal controls. Increased CD38 expression in SLE T cells correlated with plasma levels of Th2 (IL-4, IL-10, IL-13) and Th1 (IL-1ß, IL-12, IFN-γ, TNF-α) cytokines, and was more prevalent in clinically active SLE patients than in Normal controls. In contrast, elevated anti-CD38 IgG autoantibodies were more frequent in clinically quiescent SLE patients (SLEDAI=0) than in Normal controls, and correlated with moderate increased plasma levels of IL-10 and IFN-γ. However, clinically active SLE patients were mainly discriminated from quiescent SLE patients by increased levels of IL-10 and anti-dsDNA antibodies, with odds ratios (ORs) of 3.7 and 4.8, respectively. Increased frequency of anti-CD38 autoantibodies showed an inverse relationship with clinical activity (OR=0.43), and in particular with the frequency of anti-dsDNA autoantibodies (OR=0.21). Increased cell death occurred in CD38(+) Jurkat T cells treated with anti-CD38(+) SLE plasmas, and not in these cells treated with anti-CD38(-) SLE plasmas, or Normal plasmas. This effect did not occur in CD38-negative Jurkat T cells, suggesting that it could be attributed to anti-CD38 autoantibodies. These results support the hypothesis that anti-CD38 IgG autoantibodies or their associated plasma factors may dampen immune activation by affecting the viability of CD38(+) effector T cells and may provide protection from certain clinical SLE features.

Expression and purification of the recombinant His-tagged GST-CD38 fusion protein using the baculovirus/insect cell expression system.

CD38 is a type II transmembrane glycoprotein found in myriad mammalian tissues and cell types. It is known for its involvement in the metabolism of cyclic ADP-ribose and nicotinic acid adenine dinucleotide phosphate, two nucleotides with calcium mobilizing activity independent of inositol trisphosphate. CD38 itself has been shown to have clinical significance in certain diseases with possible utilization in diagnostic and prognostic applications. Previous studies on several autoimmune diseases have shown the usefulness of recombinant CD38 protein expressed from Escherichia coli and Pichia pastoris in the detection of autoantibodies to CD38 via Western blot and ELISA. In this study, we produced a 6 x His-tagged GST-CD38 fusion protein using a recombinant baculovirus/insect cell expression technique that was purified as a soluble protein. The fusion protein was purified to homogeneity by affinity and gel filtration chromatography steps. It has an apparent molecular mass of 56 kDa on SDS-PAGE gel stained with Coomassie blue and was recognized on Western blots by antibodies against human CD38 as well as the polyhistidine tag. Peptide mass fingerprinting analysis confirmed the identity of human CD38 in the fusion protein.

Identification and characterization of nuclear CD38 in the rat spleen.

CD38 is an ectoenzyme, which can produce metabolites with intracellular Ca(2+) mobilizing properties and has multiple immunological functions. However, we have recently shown that CD38 is also localized to the nucleus of rat hepatocyte whereby its metabolite cADPR, is able to mobilize nuclear Ca(2+) stores. In this study, we further characterize the localization of nuclear CD38 in the spleen, an important immune organ. We managed to detect the presence of ADP-ribosyl cyclase activity in the nuclear fraction. With Western blotting, we managed to characterize a 42-45 kDa protein band that is typical of CD38 under reducing and non-reducing conditions. However, as a comparison, other nuclear fractions from tissues like thymus, cardiac muscle and cerebellum yielded an additional 85 kDa protein band under non-reducing conditions. Both protein bands could be blocked with a CD38 blocking peptide. Immunohistochemical studies revealed the expression of CD38 in the marginal zone and in the red pulp. In contrast, the germinal center remained largely immunonegative for CD38. This is the first report of a functionally active ADP-ribosyl cyclase/CD38 in the spleen nuclear fraction. The results here suggest that the presence of CD38 in the nuclear environment might have a corollary to functional and regulatory roles in the nucleus.